pat cotroneo  fibrogen inc  zoominfocom pat cotroneos involvement in venture capital via fibrogen inc want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basepeoplepatcotroneosectionpeoplesubsectiondetailid search deals by company name industry location investors search patcotroneoget alertedif pat cotroneo gets fundedpat cotroneofibrogen inc  executive officer vice president finance and chief financial officerdeals involving pat cotroneo raised with fibrogen inc on april  raised with fibrogen inc on january  raised with fibrogen inc on december please note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completesome of the profile information was collected using the crunchbase api for more details on the profile please check pat cotroneo on crunchbaseinaccurate data help us improve whogotfunded post a comment pat carlo cotroneo  san bruno ca  intelius sign in we found pat carlo cotroneo in san bruno ca pat carlo cotroneo intelius found that pat carlo cotroneo is a male between  and  years old from san bruno ca we have connected them to  addresses  phones and  relatives or associates get report now age pat carlo cotroneo is in his s pat has lived in san bruno ca san francisco ca south san francisco ca pats relatives eileen cotroneo domenico cotroneo caternia cotroneo annamaria cotroneo pat carlo cotroneo zodiac signpisces gendermale professional status vice president finance and chief at fibrogen inc get report now want to know more about pat get a comprehensive background report find full phone numbers and other contact information when available all from billions of available public records continue below for more details about pat or use our people search engine to find others get background check on pat carlo cotroneo get a criminal check on pat carlo cotroneo get a public record report on pat carlo cotroneo get a people search report on pat carlo cotroneo pat carlo cotroneos contact information known cities lived in find out where pat carlo cotroneo has lived as well as pat carlo cotroneos phone numbers and email addresses pat carlo cotroneo has lived in  states california address for pat carlo cotroneo  p c san bruno ca has lived in san bruno ca san francisco ca get full address report phone numbers associated with pat carlo cotroneo      san bruno ca    san francisco ca get full phone report email addresses associated with pat carlo cotroneo pocom ponet accom get email report pat carlo cotroneos education information known schools attended learn about pat carlo cotroneos academic history find out which schools pat carlo cotroneo attended the dates attended as well as the degrees pat carlo cotroneo received the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act pat carlo cotroneo has attended  schools university of san francisco pat carlo cotroneo has a acccounting in acccounting sierra high school  –  pat carlo cotroneos professional information information regarding pat carlo cotroneos professional history find out previous places pat carlo cotroneo has worked as well as dates employed the following data is not guaranteed for accuracy and should not be used for employment insurance credit eligibility or for any other purpose covered under the fair credit reporting act pat carlo cotroneo has worked at  places company fibrogen inc title vice president finance and chief company fibrogen inc title chief financial officer pat carlo cotroneos experience title vice president finance and chief company fibrogen inc job details company size  mil to less than  mil  employee range  to less than  title chief financial officer company fibrogen inc job details company size  mil to less than  mil  employee range  to less than  company size  mil to less than  mil  employee range  to less than  additional professional information on pat carlo cotroneo see pat carlo cotroneos linkedin profile pat carlo cotroneos social network and potential email matches find out potential social network profiles and potential email usernamed for pat carlo cotroneo pat carlo cotroneos known social networks and potential email matches find all of pat carlo cotroneos social network profiles get full report search social networks including facebook linkedin myspace google twitter yahoo jigsaw zoominfo and more potential email matches pat cotroneo username matches patcotroneo cotroneopat patcotroneo cotroneopat patcotroneo cotroneopat patcotroneo cotroneopat pcotroneo popular email services gmailcom aolcom yahoocom comcastnet hotmailcom msncom rocketmailcom attnet sbcglobalnet ymailcom facebookcom mailcom bellsouthnet livecom earthlinknet coxnet prodigynet mecom peoplepccom junocom rediffmailcom mindspringcom comcastcom charternet outlookcom all trademarks product names company names or logos on this page are the property of their respective owners related people searches p cotroneo intelius is a leading provider of public data about people and their connections to others intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fair credit reporting act fcra this site should not be used to determine an individual’s eligibility for credit insurance employment housing or any other purpose covered by the fcra for employment or tenant screening services please visit our partner talentwise about us site map about our reports blog help contact us   –  peopleconnect inc dba intelius all rights reserved privacy policy  updated terms of service  updated what is the fcra the fair credit reporting act fcra is a federal law that promotes the accuracy fairness and privacy of information in the files of consumer reporting agencies intelius does not provide consumer reports and is not a consumer reporting agency as defined by the fcra intelius reports cannot be used for background checks related to consumer credit insurance employment housing or any other purpose prohibited under the fcra you may not use any information obtained from intelius for any purpose covered by the fcra find out more about the fcra here bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version pat cotroneo executive profile  biography  bloomberg july    am et biotechnology company overview of fibrogen inc snapshotpeople  overviewboard memberscommittees executive profile pat cotroneo chief financial officer and vice president of finance fibrogen incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriesas of fiscal year  background mr pat cotroneo has been chief financial officer of fibrogen inc since  and serves as its vice president of finance mr cotroneo joined us in  as controller prior to joining us mr cotroneo was at systemix inc where he assumed controller responsibilities for both systemix and genetic therapy inc novartis subsidiaries from  to  he was employed by deloitte  touche from  to  in various positions mr cotroneo received a bs with honors  from the university of san franciscoread full background corporate headquarters  illinois streetsan francisco california united statesphone fax  board members memberships there is no board members memberships data available education bs university of san francisco other affiliations university of san francisco annual compensation salarytotal annual compensation stocks options restricted stock awardsall other compensationexercised optionsexercised options valueexercisable optionsexercisable options valueunexercisable optionsunexercisable options valuetotal value of optionstotal number of options total compensation total annual cash compensationtotal short term compensationother long term compensationtotal calculated compensation request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationnamepositioncompanycompensationdavid a ricks chairman chief executive officer  presidenteli lilly and companycompensation as of fiscal year  sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact fibrogen inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft pat cotroneo of fibrogen inc executive profile   welcome company news company site premium log in membership home portfolio stocks bonds funds etfs cef markets tools real life finance discuss investing ideas fund analyst picks picks by category fund pick performance picks  pans enewsletter fund spy column fund spy book bond squad fund video reports fundinvestor newsletter etf investing fund family experts fund reports all fund analyst reports fund stewardship reports fund ratings highestrated value highestrated growth highestrated largecap highestrated midcap highestrated smallcap foreign fund standouts star rating performance rating methodology fund performance top month performers top ytd performers top year performers top year performers top year performers fund category returns biggest daily nav changes closedend funds exchangetraded funds quarterly market outlook fund screeners basic screeners fund screener longterm winners solid smallgrowth funds conservative bond funds premium screeners premium fund screener index funds hidden gems lowerrisk foreign funds video center fibrogen inc  fgen add to portfolioget email alertsprint this pagepdf reportdata questionquotechartstock analysisperformancekey ratiosfinancialsvaluationinsidersownershipfilingsbondsoverviewexecutive compensationinsider activitykey executivesboard of directorscommittees key executives  pat cotroneo pat cotroneo vice president finance and chief financial officer profile connections biography pat cotroneo has served as our chief financial officer since  mr cotroneo joined us in  as controller was promoted to vice president of finance and subsequently promoted to chief financial officer in  prior to joining us mr cotroneo was at systemix inc where he assumed controller responsibilities for both systemix and genetic therapy inc novartis subsidiaries from  to  prior to systemix he was employed by deloitte  touche from  to  in various positions mr cotroneo received a bs with honors from the university of san francisco and was selected a louise m davies scholar board membership pat cotroneo is not a member of any boards   we value your feedback let us know what you think site directory site map our products corrections help advertising opportunities licensing opportunities glossary rss mobile portfolio affiliate careers international sites australia canada china france germany hong kong italy the netherlands norway spain uk switzerland stocks by name  ticker  star rating  market cap  stock type  sector  industry mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name etfs by star rating  category  total assets  symbol  ticker  name articles by title  date  author  collection  interest  popularity investment categories by topic  sector  key indicators  user interest  market cap  industry premium stocks by name  ticker  star rating  market cap  stock type  sector  industry premium mutual funds by star rating  investment style  total assets  category  top holdings  top sectors  symbol  ticker  name premium etfs by star rating  category  total assets  symbol  ticker  name popular articles by title  date  author  collection  interest  popularity popular investment categories by topic  sector  key indicators  user interest  market cap  industry independent insightful trusted morningstar provides stock market analysis equity mutual fund and etf research ratings and picks portfolio tools and option hedge fund ira k and  plan research our reliable data and analysis can help both experienced enthusiasts and newcomers  copyright morningstar inc all rights reserved please read our terms of useand privacy policydow jones industrial average sp  nasdaq and morningstar index market barometer quotes are realtime russell  quote is  minutes delayed executive team  fibrogen  biopharma for anemia fibrosis cancer fibrogen china newsroom contact menu menu executive team our leadership is deeply committed to developing firstinclass medicines and bringing together a dedicated team of experts to achieve this goal thomas b neff chairman founder and chief executive officer close x close x thomas b neff chairman founder and chief executive officer mr neff founded fibrogen inc in  and has served since that time as chairman and chief executive officer and as a member of our board of directors prior to founding fibrogen mr neff was a founder and managing general partner of two investment partnerships that pioneered the use of royalty interests to fund clinical development and ultimately led to the formation of royalty pharma a global leader in the acquisition of royalty interests earlier in his career mr neff was senior vice president at lazard frères  co and an investment banker at painewebber group now ubs mr neff is a member of the board of trustees at claremont mckenna college and serves as a director of fibrogen china anemia holdings ltd and general manager of fibrogen china medical technology development co ltd he was a fellow of the thomas watson foundation and completed his undergraduate studies at claremont mckenna college with concentrations in molecular biology and government and pursued graduate studies at the university of chicago in economics and finance mr neff received a doctor of medicine degree honoris causa from oulu university oulu finland in  ‹ k peony yu mdprevious karen l bergmannext › karen l bergman vice president investor relations and corporate communications close x close x karen l bergman vice president investor relations and corporate communications ms bergman joined fibrogen as vice president investor relations and corporate communications in  she brings more than  years of experience in the pharmaceutical biotechnology and medical technology sectors she has held leadership roles in investor relations corporate product employee and financial communications and corporate marketing at a number of companies and consultancies ms bergman most recently was the president and cofounder of bcc partners llc a life sciences and healthcare investor relations and communications strategic advisory firm prior she was vice president of corporate communications and investor relations at alza corporation now johnson  johnson where she supported the company’s transition and success from an rd company developing products for leading pharmaceutical companies to a commercial organization with marketed products in multiple specialty franchise areas in oncology urology endocrinology neurology and hospital settings prior to alza she led the life sciences practice at burns mcclellan inc in new york ms bergman earned her ba at yale university where she graduated cum laude with distinction ‹ thomas b neffprevious christine l chungnext › christine l chung vice president china operations close x close x christine l chung vice president china operations ms chung is vice president china operations and managing director of our subsidiary company fibrogen china she joined the company in  and brings more than  years of experience in growing businesses from startup through various phases of corporate development ms chung serves in the role of project leader of our usbased china development efforts and has overall responsibility for our china local operations under ms chung’s leadership our china strategy has advanced from conceptualization to prelaunch prior to joining fibrogen ms chung was vice president business development at emed technologies and a management consultant with monitor group the predecessor company of monitor deloitte ms chung received her ba magna cum laude from harvard university and is a native of hong kong ‹ karen l bergmanprevious pat cotroneonext › pat cotroneo vice president finance and chief financial officer close x close x pat cotroneo vice president finance and chief financial officer mr cotroneo is our chief financial officer with responsibility for finance and accounting operations human resources and information technology mr cotroneo joined fibrogen in  and has served as our cfo since  mr cotroneo brings  years experience in senior financial management in the life sciences sector prior to joining fibrogen mr cotroneo was at systemix inc where he assumed controller responsibilities for both systemix and for genetic therapy inc now novartis from  to  prior to novartis mr cotroneo was employed for seven years by deloitte mr cotroneo received a bs degree with honors from the university of san francisco and was selected as a louise m davies scholar ‹ christine l chungprevious richard farleynext › richard farley vice president human resources close x close x richard farley vice president human resources mr farley is vice president human resources and joined fibrogen in  mr farley has more than  years of human resources experience at several leading companies prior to joining fibrogen mr farley served as vice president human resources at xenoport inc previously mr farley worked at amgen where he oversaw hr activities for numerous research and development groups in thousand oaks seattle and burnaby canada mr farley has also held human resource and administrative leadership roles at viropharma now shire plc sphinx pharmaceuticals now eli lilly eli lilly and company and hewlett packard mr farley holds a bs degree in industrial and labor relations from syracuse university and an mba from duke university ‹ pat cotroneoprevious r wayne frost pharmd jdnext › r wayne frost pharmd jd vice president regulatory affairs close x close x r wayne frost pharmd jd vice president regulatory affairs dr frost is vice president regulatory affairs and joined fibrogen in  bringing more than  years of pharmaceutical industry experience in regulatory affairs and drug development prior to joining fibrogen he served as vice president of regulatory affairs and quality assurance at sangart metabasis therapeutics inc now ligand pharmaceuticals and prometheus laboratories inc previously dr frost served as global regulatory leader for aranesp® at amgen regulatory therapeutic area head for respiratory allergy inflammation immunology and oncology at pfizer global research and development and head of regulatory for local anesthetics and critical care therapeutics at astra pharmaceuticals now astrazeneca he also worked at bayer pharmaceuticals in antibiotic drug development and at key pharmaceuticals in drug delivery dr frost is a guest lecturer on food and drug law at yale university school of medicine department of pharmacoepidemiology and public health he completed a pharmd from creighton university school of pharmacy and a postdoctoral fellowship in pharmacokineticsinfectious diseases at sunybuffalo he received a jd from the university of connecticut school of law ‹ richard farleyprevious m sean healy phdnext › m sean healy phd vice president quality close x close x m sean healy phd vice president quality dr healy is vice president quality and joined the company in  dr healy has more than  years of industry experience with  years of experience in management of quality systems and quality assurance for biotechnology companies across all stages of drug development most recently he served as vice president of quality at cellerant therapeutics where he established both the quality assurance qa and quality control qc departments including building an inhouse qc laboratory prior to cellerant dr healy led qa operations and qc for commercial product programs at ipsen and led good manufacturing practice gmp qa at theravance where he had significant responsibility for commercial preparations and launch of vibativ® dr healy also provided qa oversight for several latestage clinical and commercial products at pfizer dr healy obtained his phd in physicalanalytical chemistry from seton hall university ‹ r wayne frost pharmd jdprevious elias kouchakji mdnext › elias kouchakji md vice president clinical development drug safety and pharmacovigilance close x close x elias kouchakji md vice president clinical development drug safety and pharmacovigilance dr kouchakji vice president clinical development drug safety and pharmacovigilance joined fibrogen in  bringing more than  years of experience in product development drug safety and clinical practice previously he served as executive medical director safety at amgen inc supporting the development and commercialization of aranesp® among other programs prior dr kouchakji was the global head pharmacovigilance and risk management at elan pharmaceuticals inc now perrigo company plc head of us safety at hoffmannla roche roche and director drug safety and pharmacovigilance at serono now emd serono prior to his transition to industry dr kouchakji was a practicing physician with specialization in surgery having earned his md at damascus university ‹ m sean healy phdprevious al y lin md phdnext › al y lin md phd vice president drug development close x close x al y lin md phd vice president drug development dr lin is our vice president drug development and oversees preclinical research and development rd and chemistry manufacturing and controls cmc development and quality and supply chain management functions dr lin joined fibrogen in  and has more than  years of drug discovery development and clinical experience prior to joining fibrogen he was head of in vivo pharmacology at bayer and served as a senoir scientist at xoma corporation he received his phd from st louis university and postdoctoral training at the university of virginia he completed his clinical residency training at and received his medical degree from nanjing medical university china dr lin is a native of nanjing china ‹ elias kouchakji mdprevious michael d lowenstein jdnext › michael d lowenstein jd chief legal counsel close x close x michael d lowenstein jd chief legal counsel mr lowenstein chief legal counsel joined the company in  mr lowenstein has nearly  years of legal practice with a particular emphasis on corporate and securities law and life science transactions prior to joining fibrogen mr lowenstein practiced at wilson sonsini goodrich  rosati where he focused on corporate law securities mergers and acquisitions ma and strategic transactions he earned a jd from columbia university where he was a harlan fiske stone scholar and a ba magna cum laude from brown university mr lowenstein is a member of the state bar of california ‹ al y lin md phdprevious michael j martinelli phdnext › michael j martinelli phd vice president technical development close x close x michael j martinelli phd vice president technical development dr martinelli joined fibrogen as vice president technical development in  dr martinelli has more than  years of experience in chemical research and development automation technologies and pharmaceutical research and development he led the chemistry manufacturing and controls cmc development of numerous investigational new drug ind programs leading to many successful new drug applications ndas and product launches most recently he served as vice president pharmaceutical development for arena pharmaceuticals in san diego prior to joining arena he was executive director of research chemical process  technologies at amgen inc earlier in his career dr martinelli held numerous roles at eli lilly and company overseeing chemical process research and development he held postdoctoral fellowships at the university of munich and harvard university and was elected as a fellow to the royal society of chemistry dr martinelli has organized many international scientific conferences and is a reviewer for more than  scientific journals and an editor for scientific monographs dr martinelli received his bs in chemistry from the state university of new york at geneseo and a phd in organic chemistry from wesleyan university ‹ michael d lowenstein jdprevious james w polarek phdnext › james w polarek phd vice president protein therapeutics and collagen development close x close x james w polarek phd vice president protein therapeutics and collagen development dr polarek vice president of protein therapeutics and collagen development and board member of fibrogen europe ltd joined fibrogen in  previously dr polarek served as senior director of both tissue bioengineering research and process development at telios pharmaceuticals inc now integra lifesciences where he developed tissue engineering therapeutics designed and implemented a multidepartment team to develop manufacturing processes and managed multidisciplinary teams throughout product development dr polarek received his bs in biochemistry from ucla and his phd in biochemistry and molecular biology from the university of chicago ‹ michael j martinelli phdprevious seth porter phdnext › seth porter phd vice president fibrosis therapeutics close x close x seth porter phd vice president fibrosis therapeutics dr porter vice president fibrosis therapeutics joined fibrogen in  and has been leading the pamrevlumab development program since  he brings more than  years of clinical and preclinical experience in research drug development bioanalytics and project development across multiple therapeutic areas prior to joining fibrogen dr porter held several research and development positions in pharmaceutical and biotechnology companies in the san francisco bay area including adamas pharmaceuticals cerus corporation genentech syntex laboratories now roche and athena neurosciences acquired by elan pharmaceuticals plc he received a phd in biochemistry from dartmouth medical school in  and completed his postdoctoral training in biochemistry and neurobiology at washington university medical school ‹ james w polarek phdprevious leanne c price jdnext › leanne c price jd chief intellectual property counsel close x close x leanne c price jd chief intellectual property counsel ms price chief intellectual property counsel joined fibrogen in  she has approximately  years of inhouse and law firm experience with an emphasis on patent portfolio development and defense and intellectual property strategy in the biotechnology and pharmaceutical industries ms price was previously senior patent attorney at incyte pharmaceuticals where she was responsible for global management of incyte’s core technology portfolio prior ms price was an associate at the silicon valley law firm of skjerven morrill macpherson franklin  friel llp focused on the areas of patent prosecution and defense licensing and intellectual property counseling ms price received a bs in molecular biology and a ba in history honors with high distinction from revelle college at the university of california san diego she received her jd from boalt hall school of law university of california berkeley ms price is a member of the state bar of california and is registered to practice before the united states patent and trademark office ‹ seth porter phdprevious k peony yu mdnext › k peony yu md chief medical officer close x close x k peony yu md chief medical officer dr yu chief medical officer joined fibrogen in  dr yu oversees all global and regional clinical development strategies and execution of the various clinical programs as well as providing leadership for the roxadustat program she brings more than  years of pharmaceutical leadership patient care and drug development experience with deep expertise in all aspects of clinical and regulatory process and with multiple prior successful ndamaas for novel drugs and drugdevice combos prior to joining fibrogen dr yu served as vice president of clinical research at anesiva inc previously dr yu was director of clinical development at alza corporation now johnson  johnson director of clinical development at pain therapeutics inc and assistant director clinical development at elan corporation plc now perrigo company plc earlier in her career dr yu was head of the department of physical medicine  rehabilitation at the palo alto medical foundation dr yu received a bs in chemical engineering from university of california davis and an md from the uc davis school of medicine she completed her residency training at stanford university school of medicine dr yu is a native of china ‹ leanne c price jdprevious thomas b neffnext › our partners we are interested in building strong partnerships that complement our strengths learn more pat cotroneo profiles  facebook facebookemail or phonepasswordforgot accountenglish usespañolfrançais franceالعربيةportuguês brasilitaliano한국어deutschहिन्दीmessengerfacebook litepeopleplacesgameslocationscelebritiesmarketplacegroupsrecipesmomentsinstagramaboutcreate adcreate pagedeveloperscareersprivacycookiesad choicestermssettingsactivity log facebook   ﻿ fibrogen inc nasdaqfgen director kalevi kurkijarvi sells  shares  chaffey breeze daily ratings  news for fibrogen inc complete the form below to receive the latest headlines and analysts recommendationsfor fibrogen inc with our free daily email newsletter follow chaffeybreeze recent posts bofi holding inc bofi receives average rating of “buy” from brokerages northeast investment management sells  shares of alphabet inc nasdaqgoog brokerages set rollsroyce holding plc rr target price at  vident investment advisory llc has  position in general dynamics corporation gd oracle corporation orcl position lowered by usca ria llc exencial wealth advisors llc sells  shares of wells fargo  company nysewfc lsv asset management has  million stake in walmart stores inc wmt comcast corporation cmcsa shares bought by copeland capital management llc blue fin capital inc invests  in m company mmm hodges capital management inc sells  shares of american express company axp sawtooth solutions llc sells  shares of automatic data processing adp valero energy corporation vlo stake increased by teachers advisors llc lakeview capital partners llc acquires new stake in novartis ag nvs mckesson corporation mck stake held by bellevue group ag kinder morgan inc kmi shares bought by cypress asset management inc tx fiduciary group llc reduces stake in bp plc bp firsthand technology value fund nasdaqsvvc earns daily news sentiment score of  sasol nysessl earning somewhat positive media coverage accern reports susquehanna bancshares susq receiving favorable news coverage report finds tantech holdings nasdaqtanh earning somewhat favorable media coverage study finds fibrogen inc nasdaqfgen director kalevi kurkijarvi sells  shares posted by lucas kauffman on jul th   no comments fibrogen inc nasdaqfgen director kalevi kurkijarvi sold  shares of fibrogen stock in a transaction that occurred on monday july th the stock was sold at an average price of  for a total value of  following the completion of the sale the director now directly owns  shares in the company valued at  the sale was disclosed in a legal filing with the securities  exchange commission which is available through this hyperlink kalevi kurkijarvi also recently made the following trades get fibrogen inc alerts on thursday june th kalevi kurkijarvi sold  shares of fibrogen stock the stock was sold at an average price of  for a total value of  on tuesday may th kalevi kurkijarvi sold  shares of fibrogen stock the stock was sold at an average price of  for a total value of  shares of fibrogen inc nasdaqfgen traded down  during trading on tuesday hitting  the stock had a trading volume of  shares the stock’s  day moving average is  and its day moving average is  fibrogen inc has a month low of  and a month high of  the company’s market cap is  billion fibrogen nasdaqfgen last posted its quarterly earnings data on tuesday may th the biopharmaceutical company reported  earnings per share eps for the quarter topping the consensus estimate of  by  fibrogen had a negative return on equity of  and a negative net margin of  the business had revenue of  million for the quarter compared to analysts’ expectations of  million analysts forecast that fibrogen inc will post  earnings per share for the current year copyright violation warning “fibrogen inc nasdaqfgen director kalevi kurkijarvi sells  shares” was originally reported by chaffey breeze and is owned by of chaffey breeze if you are accessing this story on another domain it was copied illegally and republished in violation of international trademark and copyright legislation the legal version of this story can be viewed at httpswwwchaffeybreezecomfibrogenincnasdaqfgendirectorkalevikurkijarvisellsshareshtml several large investors have recently bought and sold shares of the company blackrock inc boosted its stake in fibrogen by  in the first quarter blackrock inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period fmr llc boosted its stake in fibrogen by  in the fourth quarter fmr llc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period norges bank acquired a new stake in fibrogen during the fourth quarter valued at about  vanguard group inc boosted its stake in fibrogen by  in the first quarter vanguard group inc now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period finally bogle investment management l p de boosted its stake in fibrogen by  in the first quarter bogle investment management l p de now owns  shares of the biopharmaceutical company’s stock valued at  after buying an additional  shares during the period institutional investors and hedge funds own  of the company’s stock fgen has been the topic of a number of recent research reports zacks investment research lowered fibrogen from a “hold” rating to a “sell” rating in a research note on monday may th bidaskclub raised fibrogen from a “buy” rating to a “strongbuy” rating in a research note on saturday june th william blair reissued an “outperform” rating on shares of fibrogen in a research note on monday june th citigroup inc reissued a “buy” rating and set a  price objective on shares of fibrogen in a research note on monday june th finally stifel nicolaus reissued a “buy” rating and set a  price objective up previously from  on shares of fibrogen in a research note on thursday june nd one analyst has rated the stock with a sell rating seven have issued a buy rating and one has given a strong buy rating to the company the company currently has a consensus rating of “buy” and an average target price of  about fibrogen fibrogen inc is a sciencebased biopharmaceutical company the company is engaged in the discovery development and commercialization of therapeutics to treat serious unmet medical needs its lead product candidate is roxadustat fg it is also engaged in developing products such as fg fg and fg receive news  ratings for fibrogen inc daily  enter your email address below to receive a concise daily summary of the latest news and analysts ratings for fibrogen inc and related companies with marketbeatcoms free daily email newsletter latest news leave a reply click here to cancel reply name required mail will not be published required website